Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 600%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.11 per share when it actually produced a loss of $0.01, delivering a surprise of 90.91%.Over the last four q ...